Prescient Therapeutics (ASX:PTX) lands FDA Orphan Drug status for PTX-100, shares soar – Kalkine Media
Australia's clinical-stage oncology company Prescient Therapeutics (ASX: PTX) -- developing targeted therapies (PTX-100 and PTX-200)...
Australia's clinical-stage oncology company Prescient Therapeutics (ASX: PTX) -- developing targeted therapies (PTX-100 and PTX-200)...
Clinical-stage oncology entity Prescient Therapeutics (ASX: PTX) -- focused on the development of novel and...
Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened its mark as an evolving...
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is guided by its mission to develop novel, personalised therapies for...
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) is focused on developing its innovative pipeline in personalised medicine to...
Prescient Therapeutics (ASX:PTX), an Australian biotech player developing personalised medicine therapies for cancer, has published...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical...
Prescient Therapeutics (ASX: PTX) has presented exciting new data on CellPryme-A at the 7th Annual CAR-TCR...
Prescient Therapeutics (ASX: PTX) takes a crucial step in advancing its next-generation cell therapy platform, OmniCAR. The...
Clinical-stage oncology firm Prescient Therapeutics (ASX: PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million.
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.